Guardant Health raises 2026 revenue outlook after Q1 beat

Guardant Health

07/05/2026 21:46

Overview

U.S. precision oncology firm's Q1 revenue rose 48%, beating analyst expectations

Adjusted EPS for Q1 beat analyst expectations

Company raised 2026 revenue guidance, citing strong oncology and screening growth

Outlook

Guardant Health raises 2026 revenue guidance to $1.30-$1.32 bln, up from $1.25-$1.28 bln

Company expects 2026 screening revenue of $186-$198 mln, up from prior $162-$174 mln forecast

2026 non-GAAP operating expenses now seen at $1.05-$1.07 bln, above prior $1.03-$1.05 bln range

Result Drivers

ONCOLOGY TEST VOLUME - Co said Q1 oncology revenue growth was primarily driven by a 47% increase in oncology test volume and higher reimbursement

SHIELD SCREENING VOLUME - Screening revenue growth was driven by increased Shield screening test volume and higher reimbursement

COMMERCIAL EXPANSION - Operating expenses rose due to commercial infrastructure expansion and marketing activities supporting Shield and Oncology growth

Company press release: ID:nBw5KkGWla

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$301.7 mln
$279.20 mln (19 Analysts)
Q1 Adjusted EPS
Beat
-$0.45
-$0.76 (10 Analysts)
Q1 EPS
-$0.85
Q1 Adjusted Net Income
Beat
-$58.7 mln
-$94.86 mln (10 Analysts)
Q1 Adjusted EBITDA
Miss
-$58.9 mln
-$47.72 mln (13 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 22 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Guardant Health Inc is $130.00, about 40.9% above its May 6 closing price of $92.25

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)